May 2004
Volume 45, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2004
The effect of topical cyclosporine on latanoprost–induced conjunctival inflammation
Author Affiliations & Notes
  • L. Kearsley
    Ophthalmology, Univ of Arizona, Tucson, AZ
  • L. Herrygers
    Ophthalmology, Univ of Arizona, Tucson, AZ
  • N. Kim
    Ophthalmology, Univ of Arizona, Tucson, AZ
  • J. Levine
    Ophthalmology, Univ of Arizona, Tucson, AZ
  • R. Noecker
    Ophthalmology, Univ of Arizona, Tucson, AZ
  • Footnotes
    Commercial Relationships  L. Kearsley, None; L. Herrygers, None; N. Kim, None; J. Levine, None; R. Noecker, Allergan C, R; Alcon R.
  • Footnotes
    Support  Research to prevent blindness
Investigative Ophthalmology & Visual Science May 2004, Vol.45, 4856. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Kearsley, L. Herrygers, N. Kim, J. Levine, R. Noecker; The effect of topical cyclosporine on latanoprost–induced conjunctival inflammation . Invest. Ophthalmol. Vis. Sci. 2004;45(13):4856.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: Conjunctival inflammation is a reported consequence of glaucoma therapy. Topical cyclosporine has been shown to be useful in decreasing conjunctival inflammation in dry eyes and other conditions. The purpose of this study is to evaluate whether topical cyclosporine or artificial tears influence latanoprost–induced conjunctival inflammation. Methods: Thirty–two eyes from sixteen New Zealand Rabbits were randomized to four different groups: control, latanoprost, latanoprost and topical cyclosporine, latanoprost and a BAK (benzalkonium chloride) containing artificial tear, latanoprost and a polyquad containing artificial tear. Latanoprost was administered one drop once a day. Topical cyclosporine and artificial tears were administered in a twice–daily regimen. Animals were sacrificed at 30 days, and specimens from the conjunctiva were fixed in formalin, embedded in parrafin, and stained with H&E and toluidine blue. The number of lymphocytes per high–powered field were counted in a masked fashion in both the epithelium and superficial stroma. For each conjunctival specimen, three representative sections were analyzed. These numbers were averaged and then compared using ANOVA and two–tailed paired t–tests. Results: The mean number of lymphocytes in the epithelium was 2.2, 17.5, 8.5, 34.7, and 24.8 for the control, lantanoprost, latanoprost and cyclosporine, latanoprost and polyquad tears, and latanoprost and BAK tears respectively. The mean number of lymphocytes in the superficial stroma was 0.5, 17.8, 7.2, 25.7, 14.3 respectively. There was increased inflammation compared to controls in all treatment groups receiving latanoprost alone, and latanoprost in combination with both tear solutions. There was no statistically significant difference between eyes receiving the combination of latanoprost and cyclosporine, and controls (p=0.07 for the epithelium and p=0.17 for the stroma). There was no difference between eyes treated with latanoprost alone, and latanoprost plus artificial tears (p–value <0.13). There was a decrease in inflammation in eyes treated with cyclosporine when compared to latanoprost alone, although this difference was not statistically significant (p=0.08 for both the epithelium and the stroma). Conclusions: Using either a BAK or polyquad containing artificial tear in conjunction with latanoprost does not significantly reduce drug induced conjunctival inflammation. Adding topical cyclosporine to latanoprost therapy may reduce conjunctival inflammation, although further study is necessary to confirm these results.

Keywords: conjunctivitis • drug toxicity/drug effects • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×